Culmerciclib

库莫西利

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameCulmerciclib
Drug Alias NameCulmerciclib库莫西利赛坦欣TQB-3616TQ-B3616
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4Cyclin-dependent kinase 2
Therapy Area/IndicationsMetastatic breast cancerHR-positive breast cancerLung Neoplasms +[7] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/12/09
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdLianyungang Runzhong Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesPeking UniversityNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Active IndicationsMetastatic breast cancerHR-positive breast cancerBreast Neoplasms
Inactive IndicationsLung NeoplasmsDigestive System NeoplasmsLiposarcoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A